Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Biogen
Company Monitoring Page for Biogen
latest headlines for company on cafepharma
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Reuters
Mon, 10/23/23 - 05:11 pm
Tags:
Roche
,
legal
,
Biogen
,
biosimilars
,
Actemra
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Stat
Fri, 10/20/23 - 09:57 am
Tags:
Biogen
,
Christopher Viehbacher
,
Pharma CEOs
,
risk
As 'harvest time' arrives for Alzheimer's, neuroscientist reflects on next steps for drug development
Fierce Biotech
Mon, 10/16/23 - 10:12 am
Tags:
Alzheimer's disease
,
Biogen
,
Eisai
,
Eli Lilly
,
Leqembi
,
donanemab
Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit
Fierce Pharma
Thu, 10/12/23 - 05:18 pm
Tags:
Biogen
,
Aduhelm
,
legal
,
Eisai
,
Alzheimer's disease
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Tags:
Ipsen
,
Sohonos
,
Sarepta Therapeutics
,
Elevidys
,
Biogen
,
Qalsody
,
Eisai
,
Aduhelm
,
Jazz Pharma
,
PharmaMar
,
Zepzelca
,
Acadia Pharma
,
Nuplazid
Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra
Fierce Pharma
Mon, 10/2/23 - 11:48 am
Tags:
Biogen
,
Roche
,
Actemra
,
autoimmune disease
,
biosimilars
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Reuters
Tue, 09/26/23 - 10:23 am
Tags:
Biogen
,
Eisai
,
Japan
,
Leqembi
,
Alzheimer's disease
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Mon, 09/11/23 - 11:56 am
Tags:
Alzheimer's disease
,
Eli Lilly
,
Biogen
,
Eisai
,
Leqembi
,
donanemab
Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Fierce Biotech
Thu, 08/31/23 - 11:54 am
Tags:
SAGE Therapeutics
,
layoffs
,
Biogen
,
major depressive disorcer
,
zuranolone
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
Tags:
FDA
,
Sandoz
,
Novartis
,
Gilead Sciences
,
Pfizer
,
Neurocrine
,
Regeneron
,
Ipsen
,
Revance Therapeutics
,
Delcath Systems
,
Janssen
,
Galera Therapeutics
,
Biogen
,
Roche
,
Mesoblast
,
Taiho Oncology
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
BioSpace
Fri, 08/25/23 - 09:53 am
Tags:
Biogen
,
Sandoz
,
FDA
,
biosimilars
,
MS
,
multiple sclerosis
,
Tysabri
Brii Biosciences aims to come up big where Sage and Biogen fell short
Pharma Voice
Mon, 08/21/23 - 06:53 pm
Tags:
Brii Biosciences
,
depression
,
SAGE Therapeutics
,
Biogen
,
BRII-296
,
postpartum depression
Biogen kicks off 1,000 layoffs as part of CEO Viehbacher’s ‘complete redesign’
Fierce Pharma
Fri, 08/18/23 - 11:40 am
Tags:
Biogen
,
layoffs
,
restructuring
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B
Fierce Pharma
Tue, 08/15/23 - 11:53 am
Tags:
Biogen
,
Reata Pharmaceuticals
,
M&A
,
Skyclarys
,
Friedreich’s ataxia
New Alzheimer’s drug raises hopes — along with questions
Medical Marketing and Media
Mon, 08/14/23 - 06:54 pm
Tags:
FDA
,
Alzheimer's disease
,
Eisai
,
Biogen
,
Leqembi
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
Tags:
depression
,
Biogen
,
SAGE Therapeutics
,
zuranolone
,
Intra-Cellular Therapies
,
lumateperone
,
Alto Neuroscience
,
ALTO-100
,
schizophrenia
,
Karuna Therapeutics
,
KarXT
,
Cerevel Therapeutics
,
emraclidine
,
Acadia Pharmaceuticals
,
pimavanserin
,
Axesome Therapeutics
,
AXS-05
,
Alzheimer's agitation
,
NRx
,
NRX-101
,
bipolar disorder
,
Biohaven
,
troriluzole
,
OCD
,
VistaGen
,
fasedienol
,
social anxiety
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
Motley Fool
Thu, 08/10/23 - 09:57 am
Tags:
Biogen
,
Reata Pharmaceuticals
,
M&A
,
Skyclarys
Biogen, Sage's postpartum depression approval overshadowed by larger rejection
Fierce Pharma
Mon, 08/7/23 - 12:01 pm
Tags:
SAGE Therapeutics
,
Biogen
,
FDA
,
Zurzuvae
,
postpartum depression
,
major depressive disorder
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
BioSpace
Sun, 08/6/23 - 09:39 pm
Tags:
Biogen
,
SAGE Therapeutics
,
FDA
,
Zurzuvae
,
postpartum depression
,
major depressive disorder
,
zuranolone
Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports
Fierce Pharma
Thu, 08/3/23 - 09:59 am
Tags:
Biogen
,
biosimilars
,
M&A
,
Samsung Bioepis
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
an umbrella protects you from: rain, sand, hunger
*
Fill in the blank.